Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
GARROTE-CORRAL, Sandra; SIFUENTES-GIRALDO, Walter Alberto; REGUERO-CALLEJAS, María Eugenia and VAZQUEZ-DIAZ, Mónica. Oncogenic osteomalacia secondary to phosphaturic mesenchymal tumour of the foot. Rev.Colomb.Reumatol. [online]. 2020, vol.27, n.3, pp.210-214. Epub Apr 25, 2021. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2019.09.001.
Oncogenic osteomalacia is a paraneoplastic metabolic syndrome characterised by a low phosphates in the blood due to renal phosphate losses with inadequately normal or low vitamin D levels. This disorder is associated with the release of tumour cell-secreted phosphaturic factor, most notably fibroblast growth factor 23 (FGF-23). The neoplasms related to oncogenic osteomalacia are usually small tumours of mesenchymal lineage, and they may be difficult to locate in the physical examination in some cases, due to their size and inaccessible location. The case is presented of a patient who developed vertebral and hip fractures due to oncogenic osteomalacia associated with a phosphaturic mesenchymal tumour of the deep fat tissue in the sole of the foot. This was finally diagnosed after 3 years of the onset of symptoms after being located by bone scintigraphy with Indium-111 labelled pentetreotide and magnetic resonance imaging.
Keywords : Oncogenic osteomalacia; Tumour-induced osteomalacia; Phosphaturic mesenchymal tumour; Fibroblast growth factor 23.